Knight Therapeutics Inc. announced that it has appointed Jeffrey Kadanoff as its Chief Financial Officer. Prior to joining Knight, Mr. Kadanoff was a Principal with Bain & Company where he served as a strategy consultant for 14 years. Additionally, Mr. Kadanoff was Vice President-Strategic Planning and Development at Reitmans.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.96 CAD | -0.67% | -2.30% | +14.84% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.84% | 445M | |
+9.28% | 8.74B | |
-15.14% | 4.94B | |
+50.73% | 4.7B | |
+4.36% | 3.98B | |
-26.13% | 2.28B | |
+12.07% | 2.28B | |
+16.45% | 2.14B | |
-33.59% | 2.12B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Appoints Jeffrey Kadanoff as New CFO